NCT01890213已完成1 期
A Pilot Study of Active Immunotherapy With CEA(6D) VRP Vaccine (AVX701) in Patients With Stage III Colorectal Cancer
Duke University2 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2013年11月1日最近更新:
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 12
- 试验地点
- 2
- 主要终点
- Number of participants with adverse events
研究概览
简要总结
This is a pilot study to evaluate the safety of a vaccine that consists of an alphavirus replicon (VRP) encoding the protein (CEA) that has been found to be associated with cancers such as colon cancer in patients that have stage III colon cancer. We will also evaluate the patient immune response to the vaccine.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed stage III colorectal cancer as determined by AJCC 7th edition.
- •Subjects must have received adjuvant post-operative chemotherapy meeting the following requirements:
- •Chemotherapy must have consisted of a 5-fluorouracil-based regimen with or without oxaliplatin for at least 6 cycles or capecitabine with or without oxaliplatin for 4 cycles.
- •Chemotherapy must have been completed within 1-6 months of starting study treatment.
- •Subjects with rectal cancer must have received chemotherapy meeting the following requirements:
- •Neoadjuvant chemotherapy, if utilized, must have consisted of a 5-fluorouracil-based regimen (or capecitabine) with radiation
- •Adjuvant chemotherapy must have consisted of a 5-fluorouracil-based regimen with or without oxaliplatin for at least 6 cycles or capecitabine with or without oxaliplatin for 4 cycles
- •Chemotherapy must have been completed within 1-6 months of starting study treatment.
- •Karnofsky performance status greater than or equal to 70%
- •Estimated life expectancy > 6 months and not expected to require further systemic chemotherapy for at least 3 months.
- •Age ≥ 18 years
- •Adequate hematologic function: WBC ≥ 3000/microliter, Hgb ≥ 9 g/dL (may transfuse or use erythropoietin to achieve this level), platelets ≥ 100,000/microliter
- •Adequate renal and hepatic function, with serum creatinine < 1.5 mg/dL, bilirubin < 1.5 mg/dL (except for Gilbert's syndrome which will allow bilirubin ≤ 2.0 mg/dL), ALT and AST ≤ 2.5 x upper limit of normal.
- •Ability to understand and provide signed informed consent that fulfills Institutional Review Board's guidelines.
- •Ability to return to Duke University Medical Center for adequate follow-up, as required by this protocol
排除标准
- •Patients with active cytotoxic chemotherapy or radiation therapy should be excluded. There are no exclusions based on the number of prior chemotherapy, biologic, hormonal, or experimental regimens. There must be at least 3 months between any prior CEA-targeted immunotherapy and study treatment and at least 4 weeks between any other prior therapy and study treatment.
- •Evidence of metastatic disease.
- •Patients with a history of autoimmune disease, such as but not restricted to, inflammatory bowel disease, systemic lupus erythematosus, ankylosing spondylitis, scleroderma, or multiple sclerosis.
- •Patients with serious intercurrent chronic or acute illness, such as cardiac disease (NYHA class III or IV), hepatic disease, or other illness considered by the Principal Investigator as unwarranted high risk for investigational drug treatment.
- •Patients with a medical or psychological impediment to probable compliance with the protocol should be excluded.
- •Concurrent (or within the last 5 years) second malignancy other than non melanoma skin cancer, cervical carcinoma in situ, or controlled superficial bladder cancer.
- •Presence of an active acute or chronic infection including: a urinary tract infection , HIV (as determined by ELISA and confirmed by Western Blot) or viral hepatitis (as determined by HBsAg and Hepatitis C serology). Patients with HIV are excluded based on immuno-suppression, which may render them unable to respond to the vaccine; patients with chronic hepatitis are excluded because of concern that hepatitis could be exacerbated by the injections.
- •Patients on steroid therapy (or other immuno-suppressives, such as azathioprine or cyclosporin A) are excluded on the basis of potential immune suppression. Patients must have had 6 weeks of discontinuation of any steroid therapy (except that used as pre-medication for chemotherapy or contrast-enhanced studies) prior to enrollment.
- •Patients with allergies to any component of the vaccine will be excluded from the protocol.
- •Pregnant and nursing women should be excluded from the protocol since this research may have unknown and harmful effects on an unborn child or on young children. If the patient is sexually active, the patient must agree to use a medically acceptable form of birth control while receiving treatment and for a period of 4 months following the last vaccination therapy. It is not known whether the treatment used in this study could affect the sperm and could potentially harm a child that may be fathered while on this study.
- •Patients with acute or chronic skin disorders that will interfere with injection into the skin of the extremities or subsequent assessment of potential skin reactions will be excluded.
研究组 & 干预措施
Vaccine
Experimental
AVX701 Vaccine:4 x 10EE8 IU intramuscularly every 3 weeks for 4 total immunizations
干预措施: AVX701 (Biological)
结局指标
主要结局
Number of participants with adverse events
时间窗: 12 weeks
次要结局
未报告次要终点
研究者
Michael Morse, MD
Associate Professor
Duke University
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Safety of and Immune Response to an HIV-1 Subtype C Vaccine (AVX101) in HIV Uninfected AdultsHIV InfectionsNCT00097838AlphaVax, Inc.96
已完成
2 期
Accelerated Immunization to Induce Cytomegalovirus Immunity in Stem Cell DonorsCytomegalovirus InfectionsNCT00353977National Heart, Lung, and Blood Institute (NHLBI)38
已完成
1 期
Safety of and Immune Response to Two Different HIV Vaccines, Each Followed by a Adenoviral Vaccine Boost, in HIV Uninfected AdultsHIV InfectionsNCT00270218National Institute of Allergy and Infectious Diseases (NIAID)66
已完成
1 期
Safety and Immunogenicity of a Candidate CHIKV Vaccine (CHIK001)Chikungunya FeverNCT03590392University of Oxford24
已完成
1 期
A Phase I/II Study With CEA(6D) VRP Vaccine in Patients With Advanced or Metastatic CEA-Expressing MalignanciesBreast CancerColorectal CancerLung CancerColon CancerPancreatic CancerNCT00529984AlphaVax, Inc.28